FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031844417> ?p ?o ?g. }

• W2031844417 endingPage "275" @default.
• W2031844417 startingPage "273" @default.
• W2031844417 abstract "In contrast to cortisol, adrenocorticotrophic hormone (ACTH) at pharmacological dosage lowers the serum concentrations of apolipoprotein B-containing lipoproteins, low-density lipoprotein (LDL) in particular [1, 2]. Most of the published studies on this subject are short-term, using an active fragment of ACTH (ACTH1–24) at the dose of 1.0 mg daily for four days [3]. Recently, we published the results of a dose-finding study in Basic & Clinical Pharmacology & Toxicology [3]. We found that within the dose range 0.1–1.0 mg, the LDL-lowering effect of ACTH was near linear, that this effect appeared during the second day after an ACTH injection, and that the serum LDL concentration was approaching baseline on the fourth day after an ACTH injection [1]. Thus, it seems that to achieve a steady-state of lipid metabolism, an ACTH injection is needed every other or every third day. With the consent of the local ethics committee, we extended our study to include dose intervals, in order to find the longest interval between the ACTH doses that would provide a steady-state of lipid metabolism. We recruited 32 healthy male university students of the median (range) age of 25 (19–37) years, the mean ± standard deviation body mass index 24.5 ± 2.8 kg/m2 and serum LDL cholesterol concentration 2.8 ± 0.9 mmol/l. The participants were randomized to four groups which did not differ significantly with regard to age, body weight or serum LDL cholesterol concentration. The groups were treated for a week with either NaCl 0.9% 1 ml daily intramuscularly or ACTH1–24 (Synacthen Depot 1 mg/ml, Novartis, Basel, Switzerland) 1 mg intramuscularly daily, every other day or every third day. Fasting blood samples were drawn 48 hrs after the first and the last ACTH injection. Serum LDL cholesterol and apolipoprotein B concentrations were analyzed by enzymatic methods with reagents from Roche Diagnostics GmbH (Mannheim, Germany). After confirming the normal distribution of data, the paired t-test was used for statistical analysis (Prism, GraphPad Software, USA). The results given in tables 1 & 2 show the same pattern of changes in the serum concentrations of LDL cholesterol and apolipoprotein B in all the groups. There were no changes in the NaCl group. In all the ACTH groups, significant decreases in the serum concentrations of LDL cholesterol and apolipoprotein B were observed after the first dose of ACTH. In the groups that received ACTH daily or every other day, the changes from baseline were significantly greater after the last dose as compared to the first dose. In the group that received ACTH every third day, the changes from baseline did not increase during the treatment period. As in our previous studies, the side-effects of ACTH were mainly in the form of fluid retention and insomnia. No participant in the NaCl group experienced side-effects while we received complaints from four participants in the ACTH daily group, three participants in the ACTH every other day group and one participant in the ACTH every third day group. The results indicate that if ACTH is given daily or every other day, the lowering effects of the doses on LDL cholesterol and apolipoprotein B rapidly accumulate resulting in considerable decreases in the serum concentrations. On the other hand, if ACTH is administered at longer intervals, the effect of each dose fades out before the next one is given. According to these results, ACTH must be administered at least every other day for effective reduction of the serum LDL cholesterol concentration. Unfortunately, ACTH 1 mg every other day is associated with unacceptably high incidence of side-effects. Combining the knowledge about doses [3] and intervals, the ACTH regimen of 0.5 mg every other day stands out as a plausible alternative that might give a stable, clinically significant reduction of the serum LDL cholesterol concentration with minor side-effects. This regimen deserves investigation since it might enable us to make use of ACTH's LDL cholesterol-lowering effect. Obviously, ACTH will never be prescribed solely for that purpose. However, correctly administered, ACTH could provide a stable reduction of the serum LDL cholesterol concentration which would be complementary to ACTH's other effects such as the synthesis and release of cortisol and the antiproteinuric action [4]. The above suggested total dosage of ACTH corresponding to 1.75 mg per week is known to induce a massive release of cortisol and an antiproteinuric action in those nephrotics who respond to ACTH [3, 4]." @default.
• W2031844417 created "2016-06-24" @default.
• W2031844417 creator A5020734267 @default.
• W2031844417 creator A5024057932 @default.
• W2031844417 creator A5063968897 @default.
• W2031844417 creator A5076439636 @default.
• W2031844417 date "2009-04-01" @default.
• W2031844417 modified "2023-09-23" @default.
• W2031844417 title "Search for the Optimal Dose Interval of Adrenocorticotrophic Hormone (ACTH1-24) with Regard to the Lipid-Lowering Effect" @default.
• W2031844417 cites W1996762198 @default.
• W2031844417 cites W2044512787 @default.
• W2031844417 cites W2104602296 @default.
• W2031844417 cites W2109910214 @default.
• W2031844417 doi "https://doi.org/10.1111/j.1742-7843.2009.00376.x" @default.
• W2031844417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19320635" @default.
• W2031844417 hasPublicationYear "2009" @default.
• W2031844417 type Work @default.
• W2031844417 sameAs 2031844417 @default.
• W2031844417 citedByCount "1" @default.
• W2031844417 countsByYear W20318444172012 @default.
• W2031844417 crossrefType "journal-article" @default.
• W2031844417 hasAuthorship W2031844417A5020734267 @default.
• W2031844417 hasAuthorship W2031844417A5024057932 @default.
• W2031844417 hasAuthorship W2031844417A5063968897 @default.
• W2031844417 hasAuthorship W2031844417A5076439636 @default.
• W2031844417 hasBestOaLocation W20318444171 @default.
• W2031844417 hasConcept C126322002 @default.
• W2031844417 hasConcept C134018914 @default.
• W2031844417 hasConcept C185592680 @default.
• W2031844417 hasConcept C202751555 @default.
• W2031844417 hasConcept C2778163477 @default.
• W2031844417 hasConcept C2780221984 @default.
• W2031844417 hasConcept C2780546910 @default.
• W2031844417 hasConcept C2908795159 @default.
• W2031844417 hasConcept C55493867 @default.
• W2031844417 hasConcept C57992300 @default.
• W2031844417 hasConcept C62746215 @default.
• W2031844417 hasConcept C71315377 @default.
• W2031844417 hasConcept C71924100 @default.
• W2031844417 hasConceptScore W2031844417C126322002 @default.
• W2031844417 hasConceptScore W2031844417C134018914 @default.
• W2031844417 hasConceptScore W2031844417C185592680 @default.
• W2031844417 hasConceptScore W2031844417C202751555 @default.
• W2031844417 hasConceptScore W2031844417C2778163477 @default.
• W2031844417 hasConceptScore W2031844417C2780221984 @default.
• W2031844417 hasConceptScore W2031844417C2780546910 @default.
• W2031844417 hasConceptScore W2031844417C2908795159 @default.
• W2031844417 hasConceptScore W2031844417C55493867 @default.
• W2031844417 hasConceptScore W2031844417C57992300 @default.
• W2031844417 hasConceptScore W2031844417C62746215 @default.
• W2031844417 hasConceptScore W2031844417C71315377 @default.
• W2031844417 hasConceptScore W2031844417C71924100 @default.
• W2031844417 hasIssue "4" @default.
• W2031844417 hasLocation W20318444171 @default.
• W2031844417 hasLocation W20318444172 @default.
• W2031844417 hasOpenAccess W2031844417 @default.
• W2031844417 hasPrimaryLocation W20318444171 @default.
• W2031844417 hasRelatedWork W1999190339 @default.
• W2031844417 hasRelatedWork W1999266935 @default.
• W2031844417 hasRelatedWork W2011741469 @default.
• W2031844417 hasRelatedWork W2021993512 @default.
• W2031844417 hasRelatedWork W2032958076 @default.
• W2031844417 hasRelatedWork W2044384037 @default.
• W2031844417 hasRelatedWork W2082671782 @default.
• W2031844417 hasRelatedWork W2128674471 @default.
• W2031844417 hasRelatedWork W2413517451 @default.
• W2031844417 hasRelatedWork W2411910748 @default.
• W2031844417 hasVolume "104" @default.
• W2031844417 isParatext "false" @default.
• W2031844417 isRetracted "false" @default.
• W2031844417 magId "2031844417" @default.
• W2031844417 workType "article" @default.